新闻源 财富源

2019年10月20日 星期天

康缘药业(600557)公告正文

江苏康缘药业股份有限公司2005年第一季度报告

公告日期:2005-04-23


                江苏康缘药业股份有限公司2005年第一季度报告

    1重要提示
    1.1本公司董事会及其董事保证本报告所载资料不存在任何虚假记载、误导 性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    1.2本公司负责人肖伟董事长、主管会计工作负责人穆敏财务总监及会计机 构负责人陈友龙部长声明:保证季度报告中财务会计报告真实、完整。
    1.3公司本季度财务报告未经审计。
    2公司基本情况
    2.1公司基本信息
股票简称                                                         康缘药业
股票代码                                                           600557
                                                               董事会秘书
姓    名                                                        程     凡
联系地址                                 江苏省连云港市新浦区海昌南路58号
电    话                                                     0518-5521990
传    真                                                     0518-5521983
电子信箱                                                   chf@kanion.com
    2.2财务资料
    2.2.1主要会计数据及财务指标
    单位:元
                                        本报告期末             上年度期末
总资产                              864,515,923.79         784,980,253.43
股东权益(不含少数股东权益)        421,676,526.91         409,258,961.64
每股净资产                                   2.702                  2.622
调整后的每股净资产                            2.65                  2.579
                                            报告期       年初至报告期期末
经营活动产生的现金流量净额           -8,787,013.36          -8,787,013.36
每股收益                                     0.080                  0.080
净资产收益率                                  2.94                   2.94
扣除非经常性损益后的净资产收益率              2.93                   2.93
非经常性损益项目                                                     金额
交易价格显失公允的交易产生的损益                                     0.00
处置除公司产品外的其他资产产生的损益                                 0.00
越权审批或无正式批准文件的税收返还、减免                             0.00

                                                         报告期末比上年度
                                                           期末增减(%)
总资产                                                              10.13
股东权益(不含少数股东权益)                                         3.03
每股净资产                                                           3.05
调整后的每股净资产                                                   2.75
                                                         报告期比上年同期
                                                               增减(%)
经营活动产生的现金流量净额                                          23.47
每股收益                                                            12.18
净资产收益率                                             增加0.04个百分点
扣除非经常性损益后的净资产收益率                         下降0.07个百分点
各种形式的政府补贴                                                   0.00
债务重组损益                                                         0.00
资产置换损益                                                         0.00
支付或收取并计入当期损益的资金占用费                                 0.00
短期投资收益                                                         0.00
委托投资损益                                                         0.00
扣除资产减值准备后的其他各项营业外收入、支出                   -88,667.22
因偶发原因,如因遭受自然灾害而计提的各项资产减值准备                 0.00
以前年度已经计提各项减值准备的转回                                   0.00
比较财务报表中会计政策变更对以前期间净利润的追溯调整数               0.00
中国证监会认定的其他非经常性损益项目                                 0.00
所得税影响数                                                    29,260.18
合计                                                           -59,407.04
    2.2.2利润表
                               编                                  本期数
项目
                               号             合并数               母公司
一、主营业务收入                1     146,759,737.96        93,570,903.20
减:主营业务成本                2      59,826,577.24        20,644,804.19
主营业务税金及附加              3       1,822,377.02         1,541,057.48
二、主营业务利润                4      85,110,783.70        71,385,041.53
加:其他业务利润                5         912,017.48           490,458.67
减:营业费用                    6      45,046,996.59        35,930,860.64
管理费用                        7      18,167,219.15        15,192,641.49
财务费用                        8       3,477,375.51         2,969,272.05
三、营业利润                   10      19,331,209.93        17,782,726.02
加:投资收益                   11           1,256.72           811,141.48
补贴收入                       12
营业外收入                     13           6,871.50
减:营业外支出                 14          95,538.72            60,339.00
四、利润总额                   15      19,243,799.43        18,533,528.50
减:所得税                     16       6,617,715.78         6,116,064.40
减:少数股东收益               17         208,619.55
五、净利润                     20      12,417,464.10        12,417,464.10
加:年初未分配利润             21      62,696,619.81        62,696,619.81
其他转入                       22
六、可供分配的利润             25      75,114,083.91        75,114,083.91
七、可供投资者分配的利润       35      75,114,083.91        75,114,083.91
八、未分配利润                 40      75,114,083.91        75,114,083.91

                                                   去年同期数
项目
                                               合并                母公司
一、主营业务收入                     123,662,970.71         79,830,930.09
减:主营业务成本                      51,140,942.88         14,752,252.65
主营业务税金及附加                     1,538,352.45          1,369,146.48
二、主营业务利润                      70,983,675.38         63,709,530.96
加:其他业务利润                         398,188.44            125,028.57
减:营业费用                          39,537,306.10         35,716,984.22
管理费用                              12,831,885.57         10,104,168.73
财务费用                               2,363,226.89          1,811,105.80
三、营业利润                          16,649,445.26         16,202,300.78
加:投资收益
补贴收入
营业外收入                                24,081.62             18,181.62
减:营业外支出                           192,812.38            173,740.91
四、利润总额                          16,480,714.50         16,046,741.49
减:所得税                             5,331,118.46          5,295,424.69
减:少数股东收益                          80,752.70
五、净利润                            11,068,843.34         10,751,316.80
加:年初未分配利润                    34,136,419.64         34,136,419.64
其他转入
六、可供分配的利润                    45,205,262.98         44,887,736.44
七、可供投资者分配的利润              45,205,262.98         44,887,736.44
八、未分配利润                        45,205,262.98         44,887,736.44
    2.3报告期末股东总人数及前十名流通股股东持股表
    报告期末股东总数(户)                                          18931
    前十名流通股股东持股情况
股东名称                                持股数(股)                 种类
上海市慈善基金会                             1912668                  A股
上海广通投资管理有限公司                     1220118                  A股
融通新蓝筹证券投资基金                        902000                  A股
上海上实资产经营有限公司                      300683                  A股
李含莲                                        136410                  A股
朱苏海                                        103827                  A股
陈层                                          100000                  A股
纪广祥                                        100000                  A股
王录华                                         95450                  A股
李倩                                           91570                  A股
    3管理层讨论与分析
    3.1公司报告期内经营活动总体状况的简要分析
    报告期内公司继续保持持续稳定增长。报告期内公司实现主营业务收入14675.97万元、净利润1241.75万元,较去年同期分别增长18.67%、12.18%。其中母公司实现主营业务收入9357.09万元、净利润1241.75万元,较去年同期分别增长17.21%、15.49%。
    报告期内公司募集资金项目——江苏省中药现代化技术开发中心项目进行了项目竣工决算,实际投资额2995.33万元,比计划投资的2998.50万元节余3.17万元。该中心竣工并投入运行,大大改善了公司科研装备条件,进一步提升了公司科研开发能力和技术竞争优势,为企业持续健康发展奠定了坚实基础。
    截至报告期末,公司已累计获得国家级新药证书24个,在研新药50余个,尤其热毒宁注射液、痛安注射液等2个中药注射剂新药已完成临床验证,即将获得新药证书,且抗病毒新型中药热毒宁注射液的产业化研究项目被列入了江苏省第二批科技成果转化专项资金项目,一类新药藤黄酸注射液已完成Ⅰ期临床验证,对于公司进一步优化产品结构,并从传统口服制剂向注射剂发展将起到很大推动作用;公司承担的中药现代化、国际化示范项目桂枝茯苓胶囊申报美国FDA认证工作也取得突破进展,通过了临床预审,即将直接进入美国Ⅱ期临床验证,对于公司未来开拓国际市场以及推动我国现代中药走向国际主流药品市场将会产生积极影响。
    3.1.1占主营收入或主营业务利润总额10%以上的主营行业或产品情况
    √适用      □不适用
    单位:元
分行业                         主营业务收入                  主营业务成本
医药工业                     106,454,504.39                 25,957,220.07
医药商业                      63,565,317.33                 57,129,440.93
其中:关联交易                23,260,083.76                 23,260,083.76
合计                         146,759,737.96                 59,826,577.24
分剂型                         主营业务收入                  主营业务成本
胶囊                          90,584,434.79                 17,734,720.45
口服液                         8,419,968.68                  3,248,568.21
冲剂                           2,594,336.27                  2,079,132.73
片、丸剂                       4,855,764.65                  2,894,798.68
合计                         106,454,504.39                 25,957,220.07

分行业                                                          毛利率(%)
医药工业                                                            75.62
医药商业                                                            10.12
其中:关联交易                                                         —
合计                                                                59.24
分剂型                                                          毛利率(%)
胶囊                                                                80.42
口服液                                                              61.42
冲剂                                                                19.86
片、丸剂                                                            40.38
合计                                                                75.62
    3.1.2公司经营的季节性或周期性特征
    □适用      √不适用
    3.1.3报告期利润构成情况
    √适用      □不适用
    单位:元
                                                                 本报告期
项目
                                      金额                    占利润总额%
主营业务利润                 85,110,783.70                         442.28
其它业务利润                    912,017.48                           4.74
期间费用                     66,691,591.25                         346.56
投资收益                          1,256.72                           0.01
补贴收入                              0.00                           0.00
营业外收支净额                   -88667.22                          -0.46
利润总额                     19,243,799.43                           0.00

                                               前一报告
                                                                     增减
项目
                                                              (百分点)
                                    金额      占利润总额%
主营业务利润              332,265,484.66           590.59         -148.32
其它业务利润                3,464,970.81             6.16           -1.42
期间费用                  279,306,486.43           496.46         -149.90
投资收益                    1,218,874.36             2.17           -2.16
补贴收入                       20,000.00             0.04           -0.04
营业外收支净额             -1,403,181.57            -2.49            2.03
利润总额                   56,259,661.83                             0.00
    注:1、报告期内公司主营业务利润占利润总额比例下降148.32个百分点,主要由于医药商业主营业务利润增长幅度高于医药工业,而医药商业毛利率较低,导致公司主营业务利润占利润总额比例下降较多。
    2、报告期内公司期间费用占利润总额比例下降149.9个百分点,系营业费用降低所致。
    3.1.4主营业务及其结构与前一报告期相比发生重大变化的情况及原因说明
    □适用   √不适用
    3.1.5主营业务盈利能力(毛利率)与前一报告期相比发生重大变化的情况及其原因说明
    □适用   √不适用
    3.2重大事项及其影响和解决方案的分析说明
    □适用   √不适用
    3.3会计政策、会计估计、合并范围变化以及重大会计差错的情况及原因说明
    □适用   √不适用
    3.4经审计且被出具“非标意见”情况下董事会和监事会出具的相关说明
    □适用   √不适用
    3.5  预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明
    □适用   √不适用
    3.6  公司对已披露的年度经营计划或预算的滚动调整情况
    □适用  √不适用
    江苏康缘药业股份有限公司
    董事长:肖伟
    二〇〇五年四月二十一日
    资产负债表(一)
    编制单位:江苏康缘药业股份有限公司                           单位:元
                             编                                    期末数
项目
                             号                  合并              母公司
流动资产:
货币资金                      1         94,383,480.04       76,603,429.33
短期投资                      2
应收票据                      3         22,691,508.83       21,477,636.53
应收股利                      4            115,200.00          115,200.00
应收利息                      5
应收账款                      6        203,836,153.68      131,441,012.60
其他应收款                    7         55,229,679.21       54,038,176.08
预付账款                      8         25,745,941.19       25,264,308.00
应收补贴款                    9
存货                         10         43,529,624.29       22,288,025.39
待摊费用                     11            107,666.66          107,666.66
一年内到期的长期
                             21
债权投资
其他流动资产                 24
流动资产合计                 30        445,639,253.90      331,335,454.59
长期投资:
长期股权投资                 31         12,230,597.74       40,849,943.50
长期债权投资                 32
长期投资合计                 33         12,230,597.74       40,849,943.50
固定资产:
固定资产原价                 29        366,306,771.31      345,354,590.23
减:累计折旧                 40         46,349,433.33       41,473,736.44
固定资产净值                 41        319,957,337.98      303,880,853.79
减:固定资产减值
                             42          1,553,327.85        1,351,727.88
准备
固定资产净额                 43        318,404,010.13      302,529,125.91
工程物资                     44
在建工程                     45         37,830,958.79       30,060,958.79
固定资产清理                 46
固定资产合计                 50        356,234,968.92      332,590,084.70
无形资产及其他资产:
无形资产                     51         46,560,236.07       23,517,443.15
长期待摊费用                 52          3,850,867.16        3,185,277.61
其他长期资产                 53
无形资产及其他资
                             54         50,411,103.23       26,702,720.76
产合计
递延税项:
递延税款借项                 55
资产总计                     60        864,515,923.79      731,478,203.55

                                                     期初数
项目
                                              合并                 母公司
流动资产:
货币资金                             74,331,964.34          64,537,118.93
短期投资
应收票据                             25,582,435.05          23,627,300.64
应收股利                                115,200.00             115,200.00
应收利息
应收账款                            174,291,190.73         113,273,266.88
其他应收款                           44,215,951.96          55,345,837.20
预付账款                             25,107,044.16          24,485,508.00
应收补贴款
存货                                 40,806,011.72          19,935,306.69
待摊费用                                 63,333.33              63,333.33
一年内到期的长期
债权投资
其他流动资产
流动资产合计                        384,513,131.29         301,382,871.67
长期投资:
长期股权投资                         12,229,341.02          30,038,802.02
长期债权投资
长期投资合计                         12,229,341.02          30,038,802.02
固定资产:
固定资产原价                        337,733,188.86         317,098,536.38
减:累计折旧                         43,522,702.45          39,041,231.12
固定资产净值                        294,210,486.41         278,057,305.26
减:固定资产值
                                      1,556,875.93           1,355,275.96
准备
固定资产净额                        292,653,610.48         276,702,029.30
工程物资
在建工程                             43,387,932.47          35,617,932.47
固定资产清理
固定资产合计                        336,041,542.95         312,319,961.77
无形资产及其他资产:
无形资产                             47,888,911.02          24,724,643.00
长期待摊费用                          4,307,327.15           3,581,715.49
其他长期资产                                  0.00
无形资产及其他资
                                     52,196,238.17          28,306,358.49
产合计
递延税项:
递延税款借项
资产总计                            784,980,253.43         672,047,993.95
    法定代表人:肖伟                       财务负责人:穆敏                       制表人:陈友龙
    资产负债表(二)
    编制单位:江苏康缘药业股份有限公司                                                              单位:元
                              编                       期末数
项目
                              号                 合并              母公司
流动负债:
短期借款                      61       249,000,000.00      231,000,000.00
应付票据                      62         5,174,995.94          962,170.00
应付账款                      63        87,428,571.71       27,004,959.55
预收账款                      64           701,036.45
应付工资                      65         4,088,283.75        3,211,617.62
应付福利费                    66         3,036,580.37        1,818,307.25
应付股利                      67         3,174,822.00        3,174,822.00
应交税金                      68        13,370,842.64       10,088,352.33
其他应交款                    69         2,434,594.83        2,369,225.50
其他应付款                    70        28,789,998.90       12,297,887.00
预提费用                      71           995,817.18          600,000.00
预计负债                      72
一年内到期的长期负债          78
其他流动负债                  79
流动负债合计                  80       398,195,543.77      292,527,341.25
长期负债:
长期借款                      81        19,562,452.49
应付债券                      82
长期应付款                    83
专项应付款                    84        17,346,000.00       17,346,000.00
其他长期负债                  85
长期负债合计                  87        36,908,452.49       17,346,000.00
递延税项:                    88
递延税款贷项                  89
负债合计                      90       435,103,996.26      309,873,341.25
少数股东收益                  91         7,735,400.62
所有者权益
实收资本                      92       156,060,000.00      156,060,000.00
减:已归还投资               101
实收资本净额                 102       156,060,000.00      156,060,000.00
资本公积                      93       165,648,288.04      165,576,623.43
盈余公积                      94        24,854,154.96       24,854,154.96
其中:法定公益金              95        -2,918,022.52       -2,918,022.52
未分配利润                    97        75,114,083.91       75,114,083.91
所有者权益合计                99       421,676,526.91      421,604,862.30
负债和所有者权益总计         100       864,515,923.79      731,478,203.55

                                                         期初数
项目                                             合并              母公司
流动负债:                             196,100,000.00      181,000,000.00
短期借款                                 6,885,804.85        6,885,804.85
应付票据                                80,253,036.55       24,438,583.13
应付账款                                   654,120.39
预收账款                                 4,088,283.75        3,211,617.62
应付工资                                 2,572,658.35        1,343,934.52
应付福利费                               3,174,822.00        3,174,822.00
应付股利                                 8,514,822.48        5,267,190.92
应交税金                                 2,180,898.37        2,113,073.47
其他应交款                              28,674,013.64       17,342,920.41
其他应付款                               1,024,897.85          886,750.00
预提费用
预计负债
一年内到期的长期负债
其他流动负债                           334,123,358.23      245,664,696.92
流动负债合计
长期负债:                              19,562,452.49
长期借款
应付债券
长期应付款                              17,196,000.00       17,196,000.00
专项应付款
其他长期负债                            36,758,452.49       17,196,000.00
长期负债合计
递延税项:
递延税款贷项                           370,881,810.72      262,860,696.92
负债合计                                 4,839,481.07
少数股东收益
所有者权益                             156,060,000.00      156,060,000.00
实收资本
减:已归还投资                         156,060,000.00      156,060,000.00
实收资本净额                           165,648,186.87      165,576,522.26
资本公积                                24,854,154.96       24,854,154.96
盈余公积                                -2,918,022.52       -2,918,022.52
其中:法定公益金                        62,696,619.81       62,696,619.81
未分配利润                             409,258,961.64      409,187,297.03
所有者权益合计                         784,980,253.43      672,047,993.95
负债和所有者权益总计
    法定代表人:肖伟                       财务负责人:穆敏                       制表人:陈友龙
    利润表
    编制单位:江苏康缘药业股份有限公司                                                              单位:元
                               编                                  本期数
项目
                               号             合并数               母公司
一、主营业务收入                1     146,759,737.96        93,570,903.20
减:主营业务成本                2      59,826,577.24        20,644,804.19
主营业务税金及附加              3       1,822,377.02         1,541,057.48
二、主营业务利润                4      85,110,783.70        71,385,041.53
加:其他业务利润                5         912,017.48           490,458.67
减:营业费用                    6      45,046,996.59        35,930,860.64
管理费用                        7      18,167,219.15        15,192,641.49
财务费用                        8       3,477,375.51         2,969,272.05
三、营业利润                   10      19,331,209.93        17,782,726.02
加:投资收益                   11           1,256.72           811,141.48
补贴收入                       12
营业外收入                     13           6,871.50
减:营业外支出                 14          95,538.72            60,339.00
四、利润总额                   15      19,243,799.43        18,533,528.50
减:所得税                     16       6,617,715.78         6,116,064.40
减:少数股东收益               17         208,619.55
五、净利润                     20      12,417,464.10        12,417,464.10
加:年初未分配利润             21      62,696,619.81        62,696,619.81
其他转入                       22
六、可供分配的利润             25      75,114,083.91        75,114,083.91
七、可供投资者分配的利润       35      75,114,083.91        75,114,083.91
八、未分配利润                 40      75,114,083.91        75,114,083.91

                                                     去年同期数
项目
                                                 合并              母公司
一、主营业务收入                       123,662,970.71       79,830,930.09
减:主营业务成本                        51,140,942.88       14,752,252.65
主营业务税金及附加                       1,538,352.45        1,369,146.48
二、主营业务利润                        70,983,675.38       63,709,530.96
加:其他业务利润                           398,188.44          125,028.57
减:营业费用                            39,537,306.10       35,716,984.22
管理费用                                12,831,885.57       10,104,168.73
财务费用                                 2,363,226.89        1,811,105.80
三、营业利润                            16,649,445.26       16,202,300.78
加:投资收益
补贴收入
营业外收入                                  24,081.62           18,181.62
减:营业外支出                             192,812.38          173,740.91
四、利润总额                            16,480,714.50       16,046,741.49
减:所得税                               5,331,118.46        5,295,424.69
减:少数股东收益                            80,752.70
五、净利润                              11,068,843.34       10,751,316.80
加:年初未分配利润                      34,136,419.64       34,136,419.64
其他转入
六、可供分配的利润                      45,205,262.98       44,887,736.44
七、可供投资者分配的利润                45,205,262.98       44,887,736.44
八、未分配利润                          45,205,262.98       44,887,736.44
    法定代表人:肖伟                       财务负责人:穆敏                       制表人:陈友龙
    现金流量表
    编制单位:江苏康缘药业股份有限公司                                           单位:元
项目                                           编                    合并
                                               号
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金                    1          147,063,057.47
收到的税费返还                                  2
收到的其他与经营活动有关的现金                  6              420,258.16
现金流入小计                                    5          147,483,315.63
购买商品、接受劳务支付的现金                    6           48,757,716.57
支付给职工以及为职工支付的现金                  7           22,196,473.59
支付的各项税费                                  8           18,706,054.85
支付的其他与经营活动有关的现金                  9           66,610,083.98
现金流出小计                                   10          156,270,328.99
经营活动产生的现金流量净额                     11           -8,787,013.36
二、投资活动产生的现金流量:
收回投资所收到的现金                           12
取得投资收益所收到的现金                       14
处置固定资产、无形资产和其他长期资
                                               15
产所收回的现金净额
收到的其他与投资活动有关的现金                 16
现金流入小计                                   17
购建固定资产、无形资产和其他长期资
                                               18           23,320,953.98
产所支付的现金
投资所支付的现金                               19
支付的其他与投资活动有关的现金                 20
现金流出小计                                   22           23,320,953.98
投资活动产生的现金流量净额                     25          -23,320,953.98
三、筹资活动产生的现金流量:
吸收投资所收到的现金                           26            2,687,300.00
借款所收到的现金                               28          162,900,000.00
收到的其他与筹资活动有关的现金                 29              150,000.00
现金流入小计                                   30          165,737,300.00
偿还债务所支付的现金                           31          110,000,000.00
分配股利、利润偿付利息所支付的现金             32            3,577,816.96
支付的其他与筹资活动有关的现金                 34
现金流出小计                                   36          113,577,816.96
筹资活动产生的现金流量净额                     40           52,159,483.04
四、汇率变动对现金的影响                       41
五、现金及现金等价物净增加额                   42           20,051,515.70

项目                                                               母公司
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金                                87,136,441.84
收到的税费返还
收到的其他与经营活动有关的现金                                  74,794.73
现金流入小计                                                87,211,236.57
购买商品、接受劳务支付的现金                                 8,498,648.62
支付给职工以及为职工支付的现金                              18,421,363.69
支付的各项税费                                              15,500,082.10
支付的其他与经营活动有关的现金                              56,606,573.75
现金流出小计                                                99,026,668.16
经营活动产生的现金流量净额                                 -11,815,431.59
二、投资活动产生的现金流量:
收回投资所收到的现金
取得投资收益所收到的现金
处置固定资产、无形资产和其他长期资
产所收回的现金净额
收到的其他与投资活动有关的现金
现金流入小计
购建固定资产、无形资产和其他长期资
                                                            22,955,303.27
产所支付的现金
投资所支付的现金
支付的其他与投资活动有关的现金
现金流出小计                                                22,955,303.27
投资活动产生的现金流量净额                                 -22,955,303.27
三、筹资活动产生的现金流量:
吸收投资所收到的现金
借款所收到的现金                                           150,000,000.00
收到的其他与筹资活动有关的现金                                 150,000.00
现金流入小计                                               150,150,000.00
偿还债务所支付的现金                                       100,000,000.00
分配股利、利润偿付利息所支付的现金                           3,312,954.74
支付的其他与筹资活动有关的现金
现金流出小计                                               103,312,954.74
筹资活动产生的现金流量净额                                  46,837,045.26
四、汇率变动对现金的影响
五、现金及现金等价物净增加额                                12,066,310.40
    法定代表人:肖伟               财务负责人:穆敏                制表人:陈友龙
    现金流量表补充资料
    编制单位:江苏康缘药业股份有限公司                                           单位:元
项目                                            编                   合并
                                                号
补充资料
1、将净利润调节为经营活动现金流量:
净利润                                          43          12,417,464.10
加:少数股东收益                                44             208,619.55
计提的资产减值准备                              46
固定资产折旧                                    47           4,922,555.82
无形资产摊销                                    48           1,328,674.95
长期待摊费用摊销                                49             456,459.99
待摊费用减少(减:增加)                        50
预提费用增加(减:减少)                        51             -29,080.67
处置固定资产、无形资产和其他长
                                                52                 339.00
期资产的损失(减;收益)
固定资产报废损失                                53
财务费用                                        54           3,534,308.20
投资损失(减:收益)                            55              -1,256.72
递延税款贷项(减:借项)                        56
存货的减少(减:增加)                          57          -2,463,574.79
经营性应收项目的减少(减:增加)                   58         -29,173,705.53
经营性应付项目的增加(减:减少)                   59              12,182.74
其他                                            60
经营活动产生的现金流量净额                      65          -8,787,013.36
2、不涉及现金收支的投资和筹资活动:
债务转为资本                                    66
一年内到期的可转换公司债券                      67
融资租入固定资产                                68
3、现金及现金等价物净增加情况:
现金的期末余额                                  69          94,383,480.04
减:现金的期初余额                              70          74,331,964.34
加:现金等价物的期末余额                        71
减:现金等价物的期初余额                        72
现金及现金等价物净增加额                        73          20,051,515.70

项目                                                               母公司
补充资料
1、将净利润调节为经营活动现金流量:
净利润                                                      12,417,464.10
加:少数股东收益
计提的资产减值准备
固定资产折旧                                                 4,528,330.26
无形资产摊销                                                 1,207,199.85
长期待摊费用摊销                                               396,437.88
待摊费用减少(减:增加)
预提费用增加(减:减少)                                      -286,750.00
处置固定资产、无形资产和其他长
                                                                   339.00
期资产的损失(减;收益)
固定资产报废损失
财务费用                                                     3,026,204.74
投资损失(减:收益)                                          -811,141.48
递延税款贷项(减:借项)
存货的减少(减:增加)                                      -2,352,718.70
经营性应收项目的减少(减:增加)                              -19,033,121.44
经营性应付项目的增加(减:减少)                              -10,907,675.80
其他
经营活动产生的现金流量净额                                 -11,815,431.59
2、不涉及现金收支的投资和筹资活动:
债务转为资本
一年内到期的可转换公司债券
融资租入固定资产
3、现金及现金等价物净增加情况:
现金的期末余额                                              76,603,429.33
减:现金的期初余额                                          64,537,118.93
加:现金等价物的期末余额
减:现金等价物的期初余额
现金及现金等价物净增加额                                    12,066,310.40
    法定代表人:肖伟               财务负责人:穆敏                制表人:陈友龙